Bio-Imaging Rivals Lay Patent Claims To Rest

Law360, New York (February 26, 2008, 12:00 AM EST) -- Caliper Life Sciences and AntiCancer Inc. have reached a cross-licensing deal for fluorescent imaging technology used to detect tumors, ending pending patent litigation between the bio-imaging rivals.

Under the settlement announced Tuesday, Caliber acquired the right to sublicense AntiCancer's fluorescent protein optical imaging patents to third parties. In exchange, AntiCancer may sublicense Caliper's patents regarding similar technology to a specified annual number of third parties.

The companies will also receive royalty-free licenses from each other for internal and contract research operations.

"This settlement and the resulting...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.